Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation –positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

Osimertinib is the standard of care in the initial treatment for advanced epidermal growth factor receptor (EGFR) mutation –positive lung cancer. However, clinical data and reliable prognostic biomarkers are insufficient.

Source: European Journal of Cancer - November 5, 2021 Category: Cancer & Oncology Authors: Yoshihiko Sakata, Shinya Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Ryota Shibaki, Asuka Okada, Hiroshi Kobe, Hirotaka Matsumoto, Takashi Yokoi, Yuki Sato, Takeshi Uenami, Go Saito, Yoko Tsukita, Megumi Inaba, Hideki Ikeda, Daisuke Arai, Hirotaka Tags: Original Research Source Type: research